Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

As an example, the negotiated price for ustekinumab was $4,695.00 for a ... for 11 years following FDA approval, while small-molecule drugs are exempt for only 7 years post-approval, despite ...

"Under the IRA, which discourages the research and development of additional indications for small molecule medicines ... and Johnson & Johnson's Stelara (ustekinumab). Calling the policy a ...